# A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

> **NCT00160602** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 590 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Certolizumab Pegol

## Key facts

- **NCT ID:** NCT00160602
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 590 (—)
- **Last updated:** 2020-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00160602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00160602, "A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00160602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*